Abstract
The most comprehensive review to date of research into medication treatments for alcohol use disorder (AUD) has concluded that the federally approved naltrexone and the off‐label topiramate have the strongest evidence base for reducing drinking. The report's authors lament the overall underutilization of medication treatments, citing 2019 national data showing that only an estimated 1.6% of U.S. patients with AUD reported receiving one of the approved medication treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
